Table 1.
Clinical and Hematological Characteristics of study population.
| Subject ID | UPN1 | UPN2 | UPN3 | UPN4 |
|---|---|---|---|---|
| Age (years), gender | 79, male | 70, male | 60, female | 64, male |
| Disease | RAEB-I IPSS intermediate |
RAEB-II IPSS high risk |
AML with multilineage dysplasia | AML with multilineage dysplasia |
| Cytogenetic abnormality | del(12)(p11.2p13), +8 |
-Y | normal | −7, inv (9)(p11q13), |
| Prior treatment | Azacitidine, Decitabine | Azacitadine, Revlimid (10 mg) growth factors | Azacitadine, hydroxyurea | Azacitadine, HIDAC MEC FLAG Auto BMT |
| Response to clofarabine | Stable Disease | Stable Disease | Partial Response | Refractory Disease |
| Off treatment reason | Disease progression | Disease progression | DLT-liver | Disease progression |
Abbreviations: RAEB, refractory anemia with excess blasts; AML, acute myeloid leukemia; DLT, dose limiting toxicity; HIDAC, High dose cytarabine; MEC, mitoxantrone, etoposide, cytarabine; FLAG, fludarabine, high dose cytarabine, G-CSF; IPSS, International Prognostic Scoring System; WHO, World Health Organization